Actinium shareholders re-elect Nicholson, Steinhart as Class I directors; Marcum LLP ratified as auditor

Actinium Pharmaceuticals, Inc.

David Nicholson re-elected: 3,959,659 for, 3,275,844 withheld, 9,087,835 broker non-votes.
Richard Steinhart re-elected: 5,630,379 for, 1,777,251 withheld, 9,087,835 broker non-votes.
Marcum LLP ratified as independent auditor for FY2023: 15,842,146 for, 372,774 against, 280,545 abstain.
No other matters voted on at the November 30, 2023 annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Actinium Pharmaceuticals, Inc. shareholders approved Election of David Nicholson and Richard I. Steinhart as Class I directors.

Proposal: director election
Outcome: passed

Exact text from the filing

Director For Withhold Broker Non-Votes David Nicholson 3,959,659 3,275,844 9,087,835 Richard I. Steinhart 5,630,379 1,777,251 9,087,835

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Actinium Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023.

Proposal: auditor ratification
Outcome: passed

Exact text from the filing

For Against Abstain Broker Non-Votes 15,842,146 372,774 280,545 N/A

View on SEC.gov

1179 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Actinium Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-092089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.